Although chronic HBV infection is a global health issue, there are geographical differences in the mode of transmission, prevalence and HBV genotype distribution. Chronic HBV infection is a dynamic state of interactions between HBV, hepatocytes and immune cells of the host. Accordingly, the natural history of chronic HBV infection typically starts with an immune tolerant phase, followed by an immune clearance phase and finally an inactive phase. The duration of the immune tolerant phase is usually long in chronic HBV infection acquired perinatally or in early childhood, otherwise the duration is very short. During the inactive phase, spontaneous hepatitis B surface antigen (HBsAg) seroclearance might occur at an annual rate of 1-2%; however, HBV reactivation with hepatitis activity could occur over time in one-quarter to one-third of HBsAg-seropositive patients. This occurs more frequently in males and in patients infected with genotypes D, C and B. The effort of active HBV replication-triggered immune clearance is the driving force of liver injury and subsequent disease progression in patients with hepatitis B e antigen (HBeAg)-positive or HBeAg-negative hepatitis. Clinical studies have shown that chronic HBV infection in western countries is associated with a higher incidence of cirrhosis, but lower incidence of hepatocellular carcinoma, than in Asian countries. The geographical differences in age at the time of infection and predominant HBV genotype could account for the variance in the natural history of chronic HBV infection; however, some of these differences might actually result from comparisons between cohorts with different age, gender distribution or fibrosis stage.
Chronic HBV infection is a global public health issue because of its worldwide distribution and its potential adverse sequelae, including cirrhosis, hepatic decompensation and development of hepatocellular carcinoma (HCC). The prevalence of chronic HBV infection is approximately 5% globally, but differs greatly from area to area ( Figure 1 ) [1, 2] . The prevalence of hepatitis B surface antigen (HBsAg) carriage is low (0.1-2.0%) in the United States, North and Western Europe, intermediate (2.0-8.0%) in the Mediterranean countries, Eastern Europe, Central Asia, Middle East, South America and Japan, and high (8.0-20.0%) in Southeast Asia, China, Taiwan, Alaska and subSaharan regions [3] . In high-prevalence areas, HBV infection usually occurs perinatally or during infancy and early childhood. Close contact among toddlers is considered to contribute to the maintenance of the high prevalence of HBsAg carriage in sub-Saharan areas and Alaska, whereas in other areas with high HBV prevalence, 40-50% of chronic HBV infection originates from perinatal transmission [4, 5] . In areas of intermediate endemicity, chronic HBV infection is generally caused by transmission during early childhood, mostly through household contact by 'non-parenteral' [6] or unclear parenteral mechanisms [7, 8] . In low prevalence areas, hepatitis B is typically a disease of young adults, who acquire the infection through risky behaviour, such as unprotected sexual contact or sharing of injection needles [4, 5] . HBV genotypes also have distinct geographical distribution ( Figure 1 [9] . Along with these geographical differences, the natural history of chronic HBV infection also displays geographical variation.
Natural history of chronic HBV infection
Chronic HBV infection is a dynamic state involving interactions between the virus itself, the host hepatocyte and immune response. Accordingly, the natural course of chronic HBV infection consists of changing phases. Chronic HBV infection acquired perinatally or during infancy typically has a long and uneventful immune tolerant phase. Patients in the immune tolerant phase are usually young, asymptomatic, hepatitis B e antigen (HBeAg)-seropositive with high viral loads (approximately >2×10 6 -2×10 7 IU/ml of HBV DNA), normal serum alanine aminotransferase (ALT) levels and near normal liver histology [4, 5] . Providing that serum ALT levels remain normal, there is usually no or only minimal disease progression [10] . By contrast, chronic HBV infection acquired in later life usually has a very short or no obvious immune tolerant phase [5] .
Hepatitis activity and HBeAg seroconversion during the immune clearance phase
The mechanisms triggering the loss of immune tolerance are largely unknown. The majority of patients enter the immune clearance phase after the age of 20 years. During this phase, hepatitis activity and intermittent acute ALT flares >5× the upper limit of normal (ULN) might occur and a few (<3%) might be complicated by hepatic decompensation [11] . These ALT increases and flares are considered to be the result of the host immune response against HBV with resultant apoptosis and necrosis; thus, higher ALT levels usually reflect a more vigorous endogenous immune response against HBV and more extensive hepatocyte damage [12] . The incidence of hepatitis flares varies between patient cohorts, but has reached 25% per year during the first 3-5 years of follow-up in hospital-based studies [12] [13] [14] . These events could lead to a decrease in serum HBV DNA levels and a gradual accumulation of precore or core promoter mutations [15] [16] [17] , and could eventually be followed by HBeAg clearance and appearance of its antibody (anti-HBe), defined as HBeAg seroconversion [12] . The estimated annual incidence of spontaneous HBeAg seroconversion is 2 -15%, depending on factors such as age, ALT levels and HBV genotype [12] [13] [14] [15] [16] [17] . In Taiwan, approximately 90% of children remain HBeAg-positive until 10-15 years of age and HBeAg seroconversion occurs at a mean age of 30-35 years, with 90% of HBeAg seroconversion occurring before the age of 40 years [18] . Patients infected with genotype B HBV seroconvert earlier and more frequently than patients infected with genotype C HBV [9, [18] [19] [20] [21] [22] [23] [24] . In Alaskan natives with chronic HBV infection, the 50th percentile age of HBeAg seroclearance is <20 years in patients with genotypes A, B, D and F, but >40 years in patients with genotype C [23] . In Mediterranean countries, where HBV genotype D infection is predominant, the mean age of adult patients at the time of HBeAg seroconversion was 30 years (range in one Italian study [25] . However, several field studies in Greece, where genotype D prevails by >90%, have shown repeatedly that almost 80% of the HBsAg-positive individuals are already HBeAg-negative and antiHBe-positive by the second decade of life [8, [26] [27] [28] . Moreover, follow-up studies in Greek communities with endemic HBV infection have revealed large-scale horizontal spread of HBV among infants and children with clinically silent HBeAg clearance, and that development of the HBeAg-negative/anti-HBe-positive HBsAg carrier state occurs before reaching adulthood in the vast majority of patients [7, 8, 29] . A study in the early 1970s found that most HBsAg-positive individuals aged 18-23 years (mainly Hellenic army recruits) had normal levels of hepatic enzymes, normal liver histology and numerous ground glass hepatocytes with cytoplasmic HBsAg [30] , but no hepatitis B core antigen (HBcAg) expression in the liver [27] . Subsequent studies of HBeAg status and serum HBV DNA levels have confirmed that chronic HBV infection in this population had already progressed to the HBeAg-negative carrier state [28] .
Inactive phase and spontaneous HBsAg seroclearance
HBeAg seroconversion marks the transition from the active to the inactive phase of chronic HBV infection. It is usually followed by a phase with low viral load (<10 4 -10 5 copies/ml), sustained clinical remission and a lifelong inactive state with an excellent outcome [24, 25, [31] [32] [33] [34] [35] . Spontaneous HBsAg seroclearance might occur after a prolonged period of sustained remission [32, 36, 37] . It occurs at an incidence of 0.7-2.4% per year in studies with a follow-up duration >5 years, being higher in studies with a mean or median age >40 years at time of entry. The incidence of spontaneous HBsAg seroclearance might accelerate after longer follow-up or in individuals over the age of 40-50 years to a cumulative incidence of 25% after 20 years of follow-up [36] . Besides being related to age, patients infected with genotypes A or B HBV have a higher chance of HBsAg seroclearance compared with other genotypes [37, 38] . The annual rate of spontaneous HBsAg clearance in genotype-Dinfected HBsAg-positive individuals in the inactive anti-HBe-positive phase in Greece has recently been calculated to be 1.79% [39] . HBsAg seroclearance usually confers an even better long-term outcome compared with that of inactive HBsAg carriers, provided that there is no pre-existing cirrhosis or viral superinfection; however, small amounts of HBV DNA might persist in a state of occult HBV infection. One study involving 34 consecutive patients with HBsAg seroclearance showed that 30 were still seropositive for HBV DNA (all 30 patients had HBV DNA<10 5 copies/ml with 27 patients who had <10 4 copies/ml) and that some harboured defective pre-S/S sequences, including G149R, whereas the 'a' determinant region was conserved [40] .
Reactivation of hepatitis B
After spontaneous HBeAg seroconversion, approximately 5-10% of patients still have high HBV DNA levels and persistently abnormal ALT levels, indicating direct transition from HBeAg-positive to HBeAgnegative hepatitis [29, 31, 41] . This could either be short-lived or persistent [42] . The remaining 90-95% of patients initially achieve remission, but could relapse either because of HBeAg reversion (HBeAgseropositive hepatitis) in 1-4% of patients or, in the majority of patients, because of reactivation of HBV with precore or core promoter mutations that abolish or down-regulate HBeAg production (HBeAg-negative chronic hepatitis) [17, 25, 26, 29, 31, 41, 43] . In Taiwanese studies, the estimated incidence of hepatitis relapse was 1-3% per year [14, 31, 41] , with a cumulative incidence of up to 30% after 15 years of follow-up -mostly within 10 years of HBeAg seroconversion [31, 41] . The incidence was very low in patients who HBeAg seroconverted before the age of 30 years [24, 34, 41, 44] , but was significantly higher in males, patients with genotype C infection, patients who HBeAg seroconverted after the age of 40 years [45] and in patients with serum HBV DNA levels >10 4 copies/ml within 1 year of HBeAg seroconversion [41] or at entry of the so called 'inactive carrier state' [33, 45, 46] . These age-related findings suggest that earlier HBeAg seroconversion or a shorter HBeAg-positive phase is associated with a higher chance of sustained remission [18] . A Spanish study showed that patients infected with genotypes D or F HBV had a lower chance of sustained remission after HBeAg seroconversion (61% and 50%, respectively) compared with a rate of 86% in genotype-A-infected patients [38] .
HBV precore mutations occur most frequently in genotype D infection, followed by genotypes C and B, and are seen least frequently in genotype A [47] . Long-term follow-up data from Greece have shown recently that HBV reactivation in genotype-A-infected patients following HBeAg clearance is associated with HBeAg seroreversion; however, this might escape detection if the duration of observation and serological testing are limited. In a recent study, all properly documented cases of HBeAg-negative chronic hepatitis B exhibiting persistent HBeAg-negativity/antiHBeAg positivity were found to harbour genotype D. It is, therefore, suggested that HBeAg-negative genotype A chronic HBV infection is either extremely rare or non-existent [48] . Accordingly, HBeAg-negative chronic HBV infection is most common in regions where genotype D infection dominates. The percentage of patients with chronic HBV infection who are HBeAg-negative is 80-90% in genotype-D-dominant Mediterranean areas, 30-50% in Southeast Asia and <10% in the United States and Northwestern Europe, where genotype A is prevalent and genotype D infection is relatively rare [49] . The higher incidence of HBeAg-negative hepatitis was well demonstrated in a Greek study involving 85 'inactive carriers'. During a mean follow-up period of 36 months (range 12-48), the cumulative incidence was 24% at the end of year 4 [50] . This rate was much higher than the 9.7% at year 5 and 21.6% at year 20 of follow-up reported in 1,965 inactive carriers from Taiwan [44] .
Long-term outcomes of infection
Cirrhosis, HCC or both might develop during the natural course of chronic HBV infection. Large population-based studies involving primarily (85%) HBeAg-negative HBsAg-positive patients over the age of 30 years (67% of patients were >39 years) at recruitment have shown that the risk of cirrhosis, HCC and mortality increases proportionally with HBV DNA levels ≥10 4 copies/ml [51] [52] [53] . These findings suggest that HBV replication, with subsequent immune-mediated liver injuries, is the primary driving force of disease progression [54] . Other risk factors for the development of cirrhosis include male gender, increasing age [51] [52] [53] [54] [55] [56] , HBV genotype [7, 16, 20] , persistent HBeAg seropositivity or reversion [31, 55, 57] , HBV reactivation [22, 31, 41, 44] , persistent HBV DNA seropositivity [58] and persistent ALT abnormality [59] , as well as the severity (hepatic decompensation), extent (bridging hepatic necrosis) and frequency of hepatitis flares, and the duration of hepatic lobular alterations [55] . Accordingly, patients in the inactive phase have a very low incidence of cirrhosis development [24, 25, [31] [32] [33] [34] [35] . A recent study in 4,376 HBeAgnegative patients with persistent ALT<2×ULN showed a low rate of cirrhosis (2.7%) and HCC (0.5%) during long-term follow-up (median 13 years, range 3-29). The rates were even lower in those who maintained normal ALT [35] . Similarly, an Italian study showed that the adjusted hazard ratios (95% confidence interval [CI]) for liver-related death were 33 (3.01-363) for persistently HBeAg-positive patients and 38.73 (4.65-322) for those with HBeAg-negative chronic hepatitis B or HBeAg reversion relative to inactive carriers. These data suggest that the risk of liver-related mortality in Caucasian adults with chronic hepatitis B is strongly related to sustained disease activity and ongoing high levels of HBV replication independent of HBeAg status [25] .
Approximately 50% of patients are seropositive for HBeAg or for HBV DNA (measured by hybridization assays) at the onset of cirrhosis [60, 61] , suggesting that disease progression might continue after cirrhosis develops [61] . The 5-year probability of hepatic decompensation is 15-20%, being fourfold higher in patients with active HBV replication than in patients without [62] . The estimated 5-year survival rate of patients with compensated and decompensated cirrhosis is 80-85% and 30-50%, respectively [60] .
The risk of HCC correlates with underlying liver disease and most cases of HCC develop in patients with cirrhosis; therefore, HCC and cirrhosis share the same risk factors. Patients with a family history of HCC are at increased risk [63] . Cohort studies showed that the incidence of HCC was <0.2% per year in inactive HBsAg carriers and <0.6% per year in patients with chronic hepatitis B [64] . The annual incidence of HCC in patients with cirrhosis is 2-6% [60, 61, 63] . Of the viral factors, HBV DNA level, genotype and naturally occurring mutations, such as HBV pre-S and basal core promoter A1762T/G1764A double mutations, are also associated with HCC development [9, 52, 65, 66] . A multivariate analysis involving 2,762 Taiwanese HBsAg carriers with 33,847 personyears of follow-up showed that A1762T/G1764A and genotype C were independent factors with an adjusted hazard ratio of 1.73 (P=0.013) and 1.76 (P=0.005), respectively [66] . Investigators noted that the association between HBV mutations and HCC development was most profound in patients who had a pre-S deletion followed by basal core promoter mutations, and that combination of these mutations had a synergistic effect on the development of HCC [67] . Concurrent infection with HCV, HDV or HIV also increased the risk of cirrhosis and HCC [68] . Other factors that contribute to HCC development include habitual alcohol consumption, cigarette smoking and aflatoxin exposure [68] . Studies in Africa and China showed a significant association between urinary aflatoxin levels and HCC, and a synergistic interaction with HBsAg carrier status [69] .
Geographical differences
In addition to the geographical differences in age at the time of HBV infection and the incidence of the major HBV genotypes, there are also geographical differences in the natural history of chronic HBV infection (Table 1) . Firstly, chronic HBV infection acquired perinatally or in infancy usually has a prolonged uneventful immune tolerant phase, whereas HBV infections acquired later in life have no or a very short immune tolerant phase [4, 5] . Secondly, patients infected with genotypes A, B and D HBV undergo earlier HBeAg seroconversion [9, 19, 23] , but patients infected with genotypes C and D have a higher incidence of HBeAg-negative hepatitis after spontaneous HBeAg seroconversion [22, 29, 50] . Accordingly, areas where genotypes C or D HBV are predominant have more HBeAg-negative hepatitis [17] . Thirdly, European patients predominantly (>90%) infected with genotype D seem to have a higher incidence of cirrhosis development despite early HBeAg seroconversion. This finding suggests that genotype is a more crucial factor for the difference between geographical locations. As mentioned earlier, patients infected with genotype D have a higher incidence of HBeAg-negative hepatitis [50] , which is an important risk factor for cirrhosis development. The calculated annual incidence of cirrhosis in patients with HBeAg-positive hepatitis was 3.8% in western countries compared with 1.6% in Asian countries. The corresponding figures in HBeAg-negative patients were 9.7% and 2.8% per year, respectively [64] . Of note, the factors predictive of cirrhosis were similar between western and Asian countries, including older age, histological evidence of bridging hepatic necrosis and persistent HBeAg and/or HBV DNA seropositivity [55, 64] . In addition, the incidence of cirrhosis varied among different cohorts, being lowest in inactive HBsAg carriers [24, 25, [31] [32] [33] [34] [35] , lower in HBeAg-positive young patients with normal baseline ALT [14] and considerably higher in patients with active hepatitis at entry [17, 55, 57, 58, 64, 70] . Even in patients with active hepatitis, the incidence was different between HBeAgpositive and HBeAg-negative cohorts and also different between younger and older cohorts [64] . For example, an Italian study showed that the cumulative probability of cirrhosis development after 5 and 10 years of follow-up was 5% and 46%, respectively, in patients younger than 36 years, but it was 28% and 93%, respectively, in those older than 36 years [58] . Another Italian study showed that none of the 85 paediatric patients developed cirrhosis during 15 years of follow-up [34] . Similarly, in a study from Taiwan, the incidence of cirrhosis in HBeAg-negative patients aged >50 years was 4.14%, but only 0.5% per year in those aged <30 years [44] . The calculated differences might reflect differences in the study cohorts; therefore, age, gender and stage of fibrosis should be considered in such comparisons.
HBV hepatocarcinogenesis is a multistage process involving many factors and it usually takes decades for HCC to develop. Chronic HBV infection acquired in adults has a much lower risk of HCC development than infections resulting from maternalneonatal transmission, possibly reflecting differences in the duration of infection. The risk of HCC among White asymptomatic carriers from North America and Europe is low, with an estimated annual risk of 0 and 13 per 100,000 individuals, respectively [70] [71] [72] . These figures are much lower than the annual risk of [2] and [3] .
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494 [55] and 324-1,169 [73] per 100,000 reported in two Taiwanese studies, 240 per 100,000 reported in Japan [74] and 256 per 100,000 reported in Alaska [75] . The overall annual incidence of HCC in seven studies involving 732 patients with chronic hepatitis from Europe and the United States was calculated to be 300 per 100,000. By contrast, the annual incidence calculated from nine studies involving 5,661 patients from Taiwan, China, Korea and Japan was 600 per 100,000 [64] . The risk of HCC increases further in patients with cirrhosis: in a European study involving 161 patients (89% male) with a median age of 48 years (range 17-78) who remained untreated during a follow-up period of 6.4 years, the 5-year risk of HCC was 9% and the annual incidence was 2.2% [62] . The overall annual incidence of HCC in seven studies from Europe and the United States involving 540 patients followed for 6 years was calculated to be 2.2% (95% CI 1.71-2.71) [64] . These figures are lower than a calculated annual rate of 3.7% (95% CI 3.2-4.14) [64] , based on reports from Taiwan, Japan and Asia where genotypes B and C HBV are predominant [52, [76] [77] [78] .
A recent study has shown that the intracellular expression of HBV DNA, HBcAg and cellular stress proteins are highest for genotypes B and C followed by genotype D and lowest in genotype A HBV [79] . Intracellular accumulation of HBV DNA, of HBV antigens and increased cellular stress might promote hepatocyte damage and inflammation, which could contribute to hepatocarcinogenesis [80] . In South Africa, HCC occurs in younger men who are anti-HBe-positive and non-cirrhotic. Aflatoxin exposure could also be a factor in increasing the risk of HCC [69] as could infection with genotype A 1 , which is associated with a 4.5-fold increased risk of HCC [81] .
Summary and perspectives
It is clear that chronic HBV infection is a global health issue, although there are geographical differences in the mode of transmission, prevalence and HBV genotype distribution. Typically, the natural history of chronic HBV infection starts with an immune tolerant phase followed by an immune clearance phase and finally by an inactive phase. The duration of the immune tolerant phase varies and is usually long in chronic HBV infection acquired perinatally or in infancy, but very short in infections acquired in later life. During the inactive phase, HBV reactivation followed by immune-mediated hepatocytolysis or by active hepatitis might occur in one-quarter to onethird of HBsAg-seropositive patients. Immune clearance of reactivated HBV occurs more frequently in genotype D-and C-infected patients. Clinical studies suggest that there are geographical differences in the long-term outcomes of chronic HBV infection. Geographical differences in the age of acquisition of HBV infection and in major HBV genotypes might be responsible for the geographical differences in the natural history of chronic HBV infection. However, some of the observed geographical differences might actually result from comparisons between cohorts with different distribution in age, gender or fibrosis stage -all of which also affect outcome. Finally, there is one other variable that must be considered: namely, the progressive change in the way we have looked at HBeAg-negative and anti-HBe-positive carriers over the years. Prior to the 1980s, all such patients were considered to be healthy; however, more recently, approximately 25% of patients in the Mediterranean area were found to be viraemic (based on an HBV DNA cutoff of 10 6 copies/ml -the limit of assay sensitivity at the time) and have a distinct form of HBeAg-negative/anti-HBe-positive chronic hepatitis. In the 1990s, improvements in the sensitivity of diagnostic tools (for example, PCR for HBV DNA detection) lowered the HBV DNA threshold to 10 5 copies/ ml to confirm HBV-replication-associated liver disease in these patients and, more recently, populationbased studies have identified 10 4 copies/ml as the new threshold for HBeAg-negative/anti-HBe-positive chronic HBV infection.
International studies comparing cohorts that are well matched in terms of these factors are warranted to elucidate the actual role of age of infection and of HBV genotypes in the observed geographical differences in the natural history of chronic HBV infection.
Disclosure statement
Y-FL has been involved with clinical trials or has served as a global advisory board member for Roche, Bristol-Myers Squibb, Novartis and Gilead Sciences. MRB is a member of the speakers' bureaus for F Hoffmann-La Roche, Gilead Sciences, BristolMyers Squibb, Novartis and Abbott Laboratories. SH has received research grants from Gilead Sciences and F Hoffmann-La Roche, has participated in clinical trials and has been in global advisory boards of Roche, Gilead Sciences, Bristol-Myers Squibb and Novartis.
